Trials / Sponsors / Boundless Bio, Inc.
Boundless Bio, Inc.
Industry · 3 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer | Phase 1 | 2026-02-25 |
| Terminated | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications Solid Tumor | Phase 1 | 2024-03-28 |
| Active Not Recruiting | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subj Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma | Phase 1 | 2023-03-24 |